Ernexa targets Q4 2026 for first-in-human ovarian cancer trial

July 14, 2026 9:01 AM

Ernexa Therapeutics (NASDAQ: ERNA) released a CEO video discussion on July 14, 2026, outlining the company's plans to submit an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found